Agilent Technologies Inc logo

Agilent Technologies Inc(A)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
2-STAR RATING
Consider higher Upturn Star rating
BUY for 121 days
PROFIT SINCE LAST BUY
+29.38% ▲
LAST CLOSE
$175.34
11/19/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for A

11/19/2026: A (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Agilent Technologies Inc is a prominent global life sciences and analytical instrumentation company that provides specialized laboratory equipment, software, and services. The company's primary strengths lie in its massive installed base of chromatography systems and high-margin recurring CrossLab services, which foster dependable financial resilience. Its main growth opportunity centers on expanding biopharma workflows, cell analysis, and nucleic acid therapeutics manufacturing. Key risks include exposure to cyclical biopharma spending slowdowns and intense competition from larger industry peers like Thermo Fisher Scientific. The stock suits long-term investors seeking stable exposure to healthcare and laboratory tools, with a need to monitor biopharmaceutical R&D spending trends and acquisition execution.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitAgilent delivers steady mid-single-digit organic growth with upside from biopharma and genomics, but lacks high-beta hyper-growth.
Momentum investorStrong fit while signal remains positiveConditional on a positive technical upturn signal, Agilent can experience sustained upward momentum driven by biopharma spending recovery.
Value investorMixed fitThe stock trades at premium valuation multiples typical of high-quality life science franchises, limiting deep-value bargains.
Dividend investorMixed fitAgilent pays a reliable and growing dividend, but its lower starting dividend yield appeals more to total-return than income-focused investors.
Low-risk investorStrong fitSolid balance sheet strength, high recurring revenues, and defensive healthcare/laboratory exposure make it relatively stable.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMediumThe stock experiences moderate fluctuations tied to broader market sentiment and quarterly biopharma capital spending updates.
Valuation riskMedium / highTrading at elevated price-to-earnings multiples leaves the stock sensitive to any sudden growth deceleration.
Competition risk (Thermo Fisher and Danaher)HighAgilent competes against larger, highly diversified life science giants that can bundle instruments and consumables aggressively.
Business qualityStrongAgilent features a high-quality business model underpinned by proprietary technology, high switching costs, and strong recurring service revenue.
Dividend incomeLowModest dividend yields mean the company is not structured primarily for immediate income generation.
Execution riskMediumSuccessfully integrating recent acquisitions like BIOVECTRA and scaling new manufacturing operations execution remains critical.

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 50.00B USD
Price to earnings Ratio 34.98
1Y Target Price 183.14
Price to earnings Ratio 34.98
1Y Target Price 183.14
Volume (30-day avg) 2.0M shares
Beta 1.24
52 Weeks Range 107.98 - 182.99
Updated Date 11/18/2026
52 Weeks Range 107.98 - 182.99
Updated Date 11/18/2026
Dividends yield (FY) 0.59%
Basic EPS (TTM) 5.07

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
61.0%
Active BUY / eligible
64 / 105
30-Day BUY Count Change
+16
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Diagnostics & Research

BUY participation
42.9%
Active BUY / eligible
6 / 14
30-Day BUY Count Change
-3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit 16.45%
Avg. Invested days 51
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 2.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/19/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
A receives a 4-star rating, supported by solid unit economics, solid company fundamentals, solid quantitative characteristics, and solid analyst coverage. The rating is constrained by weak price momentum, and limited analyst upside.

Company Fundamentals

★★★★★
A has solid overall fundamentals (4 stars), with solid financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, moderate earnings growth (+1.1%) and strong cash generation (FCF margin 16.6%) are partially offset by moderate revenue growth (+6.7%), very low insider ownership of 0.21%.

Financial Health Rating

★★★★★
A's financial health is supported by strong cash strength, including free-cash-flow generation of $1.2B (16.6% of revenue). Operating efficiency is solid (4 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is A's strongest growth driver at +6.7% FY2025 versus FY2024 (moderate, 3 stars). By comparison, while free-cash-flow growth (-16.1%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 95.4% and approximately 99.7% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership is only 0.21%, which materially reduces the ownership score.

Top 5 Institutional Investors

BlackRock Inc 9.08%
Vanguard Capital Management, LLC 6.54%
Vanguard Portfolio Management, LLC 5.12%
State Street Corp 4.56%
Massachusetts Financial Services Company 3.55%

Unit Economics (Per $1K Revenue)

★★★★★
A generates approximately $524 of gross profit, $213 of operating income, and $166 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Solid margins and solid cash conversion support the rating, although capital efficiency remains solid.

Economic Dimensions

★★★★★
Effective Tax Rate: 9.20%

Quantitative Style Profile

★★★★★
A has a high-quality, large-cap, liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Quality TiltHigh VolatilityLarge / Mega Cap StabilityHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Life Sciences and Applied Markets Group (LSAG)Sale of liquid and gas chromatography systems, mass spectrometers, spectroscopy instruments, and cell analysis tools.This is the core equipment engine that places hardware instruments into labs globally.
Agilent CrossLab Group (ACG)Recurring revenue from laboratory services, maintenance contracts, software licenses, training, and chemical consumable supplies.Provides a predictable, high-margin stream of recurring revenue that buffers against hardware cycle swings.
Diagnostics and Genomics Group (DGG)Reagents for cancer pathology (Dako), nucleic acid therapeutics manufacturing, and genomic research tools.Captures high-value clinical diagnostic and precision medicine revenue streams.
Geographic ExposureGlobal sales spanning the Americas, Europe, and Asia-Pacific (including significant volume in China).International diversification provides broad market reach but exposes earnings to regional macroeconomic and currency shifts.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-23
When After Market
Estimate 1.72
Actual -

Profitability

Profit Margin 19.53%
Operating Margin (TTM) 24.54%

Management Effectiveness

Return on Assets (TTM) 8.63%
Return on Equity (TTM) 20.97%

Valuation

Trailing PE 34.98
Forward PE 25.51
Enterprise Value 50.74B
Price to Sales(TTM) 6.78
Enterprise Value 50.74B
Price to Sales(TTM) 6.78
Enterprise Value to Revenue 6.88
Enterprise Value to EBITDA 24.94
Shares Outstanding 281.97M
Shares Floating 281.23M
Shares Outstanding 281.97M
Shares Floating 281.23M
Percent Insiders 0.21
Percent Institutions 95.37

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.